In this study, mutations identified in genes (i.e., TSC1, TSC2, MTOR, and IRS1) that were shared by the three pathways (PI3K/AKT, mTOR and AMPK), strongly suggested that targeting these pathways or genes may present promising strategies for GIST prevention and treatment. Here, TSC1 is linked to gastrointestinal stromal tumor.